InsiderSignal.AI

InsiderSignal.ai

LQDA - Liquidia Corp

Insider Sale by Jeffs Roger (CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Jeffs Roger, serving as CEO at Liquidia Corp (LQDA), sold 53,300 shares at $40.21 per share, for a total transaction value of $2,143,323.00. Following this transaction, Jeffs Roger now holds 2,626,128 shares of LQDA.

This sale represents a 2.00% decrease in Jeffs Roger's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, April 14, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, April 16, 2026, 2 days after the trade was made.

Liquidia Corp operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Jeffs Roger

Jeffs Roger

CEO

Dr. Roger Jeffs is a seasoned biopharmaceutical executive serving as CEO of Liquidia Corporation (LQDA) since January 2022, where he leads the development of therapies for pulmonary hypertension and pulmonary arterial hypertension.[[1]](https://www.aimasterclass.com/person/roger-jeffs)[[2]](https://theorg.com/org/liquidia/org-chart/roger-jeffs)[[5]](https://www.zoominfo.com/p/Roger-Jeffs/619870) He recently engaged in insider trading, selling 30,610 shares of LQDA on June 4, 2025, and holds approximately 2.6 million shares valued at over $47 million as of that date.[[3]](https://www.gurufocus.com/insider/33473/roger-jeffs) Dr. Jeffs earned a Bachelor's degree in Chemistry from Duke University (1980-1984) and a PhD in Pharmacology from the University of North Carolina School of Medicine (1991).[[1]](https://www.aimasterclass.com/person/roger-jeffs)[[2]](https://theorg.com/org/liquidia/org-chart/roger-jeffs)[[4]](https://kriyatherapeutics.com/roger-jeffs-phd/) His career highlights include an 18-year tenure at United Therapeutics Corporation (1998-2016), rising from Director of Research to President and co-CEO, overseeing the IPO, approval of six rare disease products, and growth to a $1.5B revenue run rate.[[1]](https://www.aimasterclass.com/person/roger-jeffs)[[2]](https://theorg.com/org/liquidia/org-chart/roger-jeffs)[[4]](https://kriyatherapeutics.com/roger-jeffs-phd/) Previously at Amgen and Burroughs Wellcome, he now serves on boards including Axsome Therapeutics and Albireo Pharma, co-founded Kriya Therapeutics as Vice Chairman, and owns Bull City Select Investments.[[1]](https://www.aimasterclass.com/person/roger-jeffs)[[2]](https://theorg.com/org/liquidia/org-chart/roger-jeffs)[[3]](https://www.gurufocus.com/insider/33473/roger-jeffs)[[4]](https://kriyatherapeutics.com/roger-jeffs-phd/)

View full insider profile →

Trade Price

$40.21

Quantity

53,300

Total Value

$2,143,323.00

Shares Owned

2,626,128

Trade Date

Tuesday, April 14, 2026

3 days ago

SEC Filing Date

Thursday, April 16, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Liquidia Corp

Company Overview

No company information available
View news mentioning LQDA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5698943

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime